Last updated: July 20, 2026
Boehringer Ingelheim v. Zydus Pharmaceuticals (USA) Inc. 1:18-cv-01763: litigation summary, Paragraph IV posture, and what’s at risk
Boehringer Ingelheim Pharmaceuticals Inc. sued Zydus Pharmaceuticals (USA) Inc. in the District of New Jersey under the Hatch-Waxman framework in case number 1:18-cv-01763, filed Oct. 19, 2018. The record indicates a patent infringement dispute tied to Zydus’s FDA-directed generic strategy, with Boehringer pursuing remedies for infringement of one or more Orange Book-listed patents. The case’s litigation posture, deadlines, and settlement or final disposition cannot be accurately summarized from the information provided.
What is the case timeline for Boehringer Ingelheim Pharmaceuticals v. Zydus 1:18-cv-01763?
Filed: Oct. 19, 2018
Court: U.S. District Court for the District of New Jersey
Case number: 1:18-cv-01763
Parties:
- Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc.
- Defendant: Zydus Pharmaceuticals (USA) Inc.
What are the procedural milestones usually reflected in this docket?
Typical Hatch-Waxman generic-IP dockets include:
- Complaint filing after an ANDA submission and required notice of Paragraph IV challenges
- Motion practice on pleadings, claim construction, and preliminary injunction standards
- Expert and discovery schedule
- Potential settlement leading to covenant or dismissal
- Final judgment and/or consent judgment, sometimes with stipulations tied to FDA entry timing
Which patents were asserted in Boehringer v. Zydus 1:18-cv-01763?
No asserted-patent numbers, expiration dates, or claim targets are included in the input. A litigation analysis that names specific patents (and their legal categories such as composition, formulation, method of use, or process) requires the complaint, infringement contentions, or docket attachments.
Was this a Paragraph IV ANDA challenge, and what does that imply for launch timing?
Under Hatch-Waxman practice, a generic defendant’s FDA submission plus a notice of infringement typically drives:
- The 30-month stay triggered by a timely Paragraph IV notice and suit
- A patent-by-patent infringement framework in which “at-risk” entry depends on whether the patents are found infringed or invalid, or whether a settlement carves out market-entry dates
The provided input does not state:
- The ANDA drug product name or NDA reference product
- Whether the asserted patents were challenged under Paragraph IV
- Any 30-month stay date or any FDA eligibility outcome
What is the Orange Book status for the Boehringer product at issue in 1:18-cv-01763?
Orange Book status requires:
- the reference listed drug (RLD)
- the listed patents and their listing codes (drug substance, drug product, method of use)
- the applicable expiration dates and any pediatric exclusivity extensions
Those specifics are not present in the input, so an Orange Book-based exclusivity and exclusivity stacking analysis cannot be produced accurately.
How strong was Boehringer’s patent estate in this dispute?
Patent strength analysis depends on:
- which asserted patents were in suit
- their claim scope and how the accused product design mapped to the claims
- prior art and validity arguments raised in the case
- claim construction rulings (Markman decisions) and their effect on infringement and validity
No asserted-patent or court-ruling content is included in the input.
What claims typically matter most in Hatch-Waxman pharma disputes?
- Composition-of-matter claims for the active ingredient (or polymorph/solvate forms)
- Formulation claims (matrix, excipient system, particle size ranges)
- Method-of-use claims (indication, dosing regimen, patient population)
- Process claims (manufacturing route, purification steps, specific intermediates)
The input does not indicate which of these categories were litigated.
What arguments did Zydus raise to invalidate or avoid infringement?
A litigation analysis requires the invalidity and non-infringement positions pleaded in:
- the answer and counterclaims
- the invalidity contentions
- claim construction briefing
- summary judgment motions and Daubert or expert reports
Those elements are not present in the input, so the analysis cannot be completed.
Were there Markman rulings, claim construction outcomes, or injunction decisions?
Court outcomes materially affect:
- how narrowly the asserted claims are interpreted
- whether Zydus’s generic design avoids infringement
- whether a preliminary injunction issues or is denied
No docket disposition, claim construction transcript summary, or injunction rulings are included in the input.
Did the parties settle, and what were the consequences for FDA approval and market entry?
Settlement in Hatch-Waxman disputes typically includes:
- a stipulated entry date
- carve-outs tied to specific strengths, dosage forms, or NDCs
- mutual covenants not to sue
- dismissal with or without prejudice
- agreements addressing FDA labeling and launch sequencing
No settlement terms or dismissal/conclusion status are included in the input.
What is the revenue and generic-entry exposure linked to 1:18-cv-01763?
Revenue exposure analysis requires at least:
- the drug’s therapeutic area and marketed product sales during the relevant period
- whether the dispute involved a high-selling strength or an all-strength portfolio
- the timing of exclusivity and patent expiry and whether a 180-day exclusivity trigger occurred
The input provides no drug identity, sales, or entry timing.
How does Zydus’s case posture compare with other Boehringer generic litigations?
Comparative analysis requires:
- other Boehringer v. generic defendant cases
- their asserted patents, outcomes, and settlement dates
- commonality of the challenged claims and generic design workarounds
No comparable case list or outcomes are included in the input.
What manufacturing/IP barriers would apply if Zydus attempted “design-around” work?
Design-around risk depends on the claim scope and the accused product parameters:
- particle size and polymorph control (for composition patents)
- formulation excipient ranges and manufacturing conditions (for product patents)
- dosing regimen parameters (for method-of-use)
- process intermediates (for process patents)
The input does not identify the accused product or asserted claim limitations.
Key Takeaways
- The lawsuit Boehringer Ingelheim Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. is identified as 1:18-cv-01763 in the District of New Jersey, filed Oct. 19, 2018.
- The input does not include the asserted patent numbers, drug identity, Paragraph IV posture, court rulings, or settlement/final disposition, so a complete litigation summary and infringement/validity analysis cannot be produced from the provided content.
FAQs
-
What is the court and filing date for Boehringer Ingelheim v. Zydus 1:18-cv-01763?
District of New Jersey; filed Oct. 19, 2018; case number 1:18-cv-01763.
-
What is the Hatch-Waxman significance of 1:18-cv-01763?
The case is consistent with a Hatch-Waxman patent challenge suit, but the Paragraph IV details are not provided in the input.
-
Which patents are at issue in 1:18-cv-01763?
Not provided in the input.
-
Was there a 30-month stay or an injunction in 1:18-cv-01763?
Not provided in the input.
-
Did Zydus launch “at risk,” or was entry delayed by settlement?
Not provided in the input.
References
- U.S. District Court for the District of New Jersey. Boehringer Ingelheim Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:18-cv-01763 (filed Oct. 19, 2018).
